Venus Remedies has added one more patent to its kitty for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. After Potentox, this is the company’s second patent grant from the Australian Patent office (APO), Government of Australia, and is valid till February 2026.
The total market size of MRSA in the world accounts for $9 billion. At present, it is growing at CAGR of 4.8 percent which is estimated to reach $12.40 billion by 2017. The company expects to grab a fair share of this market within 3 years of launch of its novel research product Vancoplus in all major territories of the world.
Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medical Research Center Team. The formulation is the most effective and safe option available in the market to curb the notorious methicillin resistant staphylococcus.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |